Annual report
4578.TEDINET S100XUA7
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 149
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.47T | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.33T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.02T | 2023-01-01 → 2023-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.50T | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥479.4bn | 2025-01-01 → 2025-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥323.6bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥468.0bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥335.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥142.7bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥163.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥363.1bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥343.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥121.6bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥133.9bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥125.5bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥366.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥347.3bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥4.20T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.74T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.36T | at 2023-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥3.10T | at 2022-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.82T | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.10T | at 2025-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥961.1bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.10T | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.78T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥3.03T | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.73T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.39T | at 2023-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥2.23T | at 2022-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥2.01T | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥534.6bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥426.2bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥410.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥403.6bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥354.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥283.2bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥228.9bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥161.6bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥265.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥190.5bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥95.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥137.3bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥189.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.3bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥95.8bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥685.06 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥633.76 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥224.1 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥246.8 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥231.32 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥246.78 | 2022-01-01 → 2022-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥231.15 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥5,743.73 | at 2025-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥5,089.58 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,410.8 | at 2023-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,100.84 | at 2022-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,707.64 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 72.3% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.1% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.2% | at 2023-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.3% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 12.6% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.4% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 5.3% | 2023-01-01 → 2023-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.3% | 2022-01-01 → 2022-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.5% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 37,758 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 35,338 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 34,388 | at 2023-12-31v | Cons. | Number of employees |
| Employees | 33,482 | at 2022-12-31v | Cons. | Number of employees |
| Employees | 33,226 | at 2021-12-31d | Cons. | Number of employees |
| Revenue | ¥98.8bn | 2025-01-01 → 2025-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥118.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥82.4bn | 2023-01-01 → 2023-12-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥57.0bn | 2022-01-01 → 2022-12-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥115.0bn | 2021-01-01 → 2021-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥82.7bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥102.9bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥84.2bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥105.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥70.0bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥46.4bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥104.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥88.4bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥105.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥89.9bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥106.4bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥71.0bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥47.4bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥106.0bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.32T | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥1.38T | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.21T | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.27T | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.25T | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥298.8bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥309.6bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.03T | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.07T | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.08T | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥1.06T | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.07T | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥101.5bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥130.4bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥169.52 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.52 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.92 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.37 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.5 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥140 | 2025-01-01 → 2025-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥120 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2023-01-01 → 2023-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2022-01-01 → 2022-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,941.14 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,997.67 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,989.83 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,959.51 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,970.44 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 77.4% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.6% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.6% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.6% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2023-01-01 → 2023-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2022-01-01 → 2022-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 542,988,917 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 552,024,717 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 224 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 183 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 147 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 137 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 61
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-01-01 → 2025-12-31 | ¥9.0bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥56.8bn |
| Consumer Productsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥5.1bn |
| Consumer Productsreportable segment | employees | at 2025-12-31 | 590 pure |
| Consumer Productsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥34.6bn |
| Consumer Productsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥34.6bn |
| Consumer Productsreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥24m |
| Consumer Productsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥25.1bn |
| Nutraceuticalsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥38.9bn |
| Nutraceuticalsreportable segment | employees | at 2025-12-31 | 9625 pure |
| Nutraceuticalsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥577.7bn |
| Nutraceuticalsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥577.6bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥48m |
| Nutraceuticalsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥57.7bn |
| Otherreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥17.6bn |
| Otherreportable segment | employees | at 2025-12-31 | 3143 pure |
| Otherreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥115.9bn |
| Otherreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥112.4bn |
| Otherreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥3.5bn |
| Otherreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥8.0bn |
| Pharmaceuticalsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥221.7bn |
| Pharmaceuticalsreportable segment | employees | at 2025-12-31 | 22897 pure |
| Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥1.74T |
| Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥1.74T |
| Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥445.3bn |
| —segment total | capex | 2025-01-01 → 2025-12-31 | ¥283.3bn |
| —segment total | employees | at 2025-12-31 | 36255 pure |
| —segment total | revenue | 2025-01-01 → 2025-12-31 | ¥2.47T |
| —segment total | revenue external | 2025-01-01 → 2025-12-31 | ¥2.47T |
| —segment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥3.6bn |
| —segment total | segment profit | 2025-01-01 → 2025-12-31 | ¥536.2bn |
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥9.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥51.8bn |
| Consumer Productsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥33.8bn |
| Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥33.8bn |
| Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥7m |
| Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥23.0bn |
| Nutraceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥54.2bn |
| Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥557.0bn |
| Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥557.0bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥37m |
| Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥59.8bn |
| Otherreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥7.7bn |
| Otherreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥113.7bn |
| Otherreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥110.1bn |
| Otherreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Otherreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥7.5bn |
| Pharmaceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥252.0bn |
| Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.63T |
| Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.63T |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥285.1bn |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥317.4bn |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥2.33T |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥2.33T |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥375.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,288
| Item | Context | Value | Unit |
|---|---|---|---|
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。当社の単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行㈱(信託口) | |
| Address major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂1-8-1 赤坂インターシティAIR | |
| Name major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)野村信託銀行㈱ 大塚創業家持株会信託口 | |
| Address major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町2-2-2 | |
| Name major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)㈱日本カストディ銀行(信託口) | |
| Address major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)東京都中央区晴海1-8-12 | |
| Name major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)大塚グループ従業員持株会 | |
| Address major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)東京都港区港南2-16-4 品川グランドセントラルタワー | |
| Name major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)㈱阿波銀行 | |
| Address major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)徳島県徳島市西船場町2-24-1 | |
| Name major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)JP MORGAN CHASE BANK 385781(常任代理人 ㈱みずほ銀行決済営業部) | |
| Address major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)㈱りそな銀行 | |
| Address major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区備後町2-2-1 | |
| Name major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)㈱メディパルホールディングス | |
| Address major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)東京都中央区京橋3-1-1 | |
| Name major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)日亜化学工業㈱ | |
| Address major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)徳島県阿南市上中町岡491-100 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | - | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithFullVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentYearInstant_SharesLessThanOneUnitMember | Original text (Japanese)1単元(100株)未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentYearInstant_Row1Member | Original text (Japanese)大塚ホールディングス㈱ | |
| Address of shareholder treasury shares etc | CurrentYearInstant_Row1Member | Original text (Japanese)東京都千代田区神田司町2-9 | |
| Classes of shares etc (text) | FilingDateInstant | Text · Plus | |
| Acquisitions by resolution of shareholders meeting (text) | FilingDateInstant | Text · Plus | |
| Acquisitions by resolution of board of directors meeting (text) | FilingDateInstant | Text · Plus | |
| Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text) | FilingDateInstant | Text · Plus | |
| Disposals or holding of acquired treasury shares (text) | FilingDateInstant | Text · Plus | |
| Dividend policy (text) | FilingDateInstant | Text · Plus | |
| Date of resolution dividends of surplus | FilingDateInstant_Row1Member | 2025-07-31 | |
| Resolution dividends of surplus | FilingDateInstant_Row1Member | Original text (Japanese)取締役会決議 | |
| Date of resolution dividends of surplus | FilingDateInstant_Row2Member | 2026-02-13 | |
| Resolution dividends of surplus | FilingDateInstant_Row2Member | Original text (Japanese)取締役会決議 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |